Fluticasone Use During Pregnancy
Fluticasone (both inhaled and intranasal formulations) is safe to use during pregnancy and should be continued at the lowest effective dose to maintain disease control. 1
Safety Profile and Evidence
Inhaled corticosteroids, including fluticasone, have not been associated with increased risk of major congenital malformations, intrauterine growth restriction, preterm delivery, or low birth weight at usual therapeutic doses. 1
Key Safety Data:
- Fluticasone is classified as FDA Pregnancy Category C, but this reflects lack of controlled human studies rather than evidence of harm 2
- The European Respiratory Society/Thoracic Society of Australia and New Zealand designates fluticasone as "compatible" for use during pregnancy 1
- A large UK population-based cohort study of 5,362 pregnancies found no increased risk of major congenital malformations with first-trimester fluticasone exposure compared to other inhaled corticosteroids (adjusted OR 1.2,95% CI 0.7-2.0) 3
- A meta-analysis confirmed that intranasal corticosteroids during pregnancy do not increase risks of major malformations, preterm delivery, low birth weight, or pregnancy-induced hypertension 1
Clinical Recommendations
For Asthma Management:
- Continue fluticasone if the patient was well-controlled on it pre-pregnancy 1
- Use the lowest dose necessary to maintain asthma control 1
- While budesonide has more extensive pregnancy safety data and is technically preferred when initiating therapy, switching from fluticasone to budesonide is unnecessary if asthma is already well-controlled 1
For Rhinitis/Rhinosinusitis:
- All modern intranasal corticosteroids including fluticasone propionate and fluticasone furoate are safe at recommended doses 1
- Intranasal fluticasone has reassuring safety data with accumulated evidence supporting its use 1
- If initiating intranasal corticosteroid therapy during pregnancy, budesonide (Pregnancy Category B) may be marginally preferred due to more extensive human data, but continuing pre-pregnancy fluticasone is entirely reasonable 1
Important Caveats and Considerations
Dose-Related Concerns:
- One study suggested that beclomethasone doses >1000 µg/day may be associated with a small increased risk of congenital malformations 1
- This threshold concern likely applies to all inhaled corticosteroids, emphasizing the importance of using the minimum effective dose 4
- The risks of poorly controlled asthma (maternal hypoxia, preeclampsia, preterm delivery) far outweigh theoretical medication risks 4
Formulation-Specific Notes:
- Intranasal fluticasone propionate showed no efficacy benefit over placebo in one small study of pregnancy rhinitis, though safety was confirmed 5
- Despite this single negative efficacy study, intranasal fluticasone remains a reasonable option given its established safety profile 6
- Systemic absorption from intranasal administration is substantially lower than from inhaled formulations 7
FDA Label Information:
- Animal studies showed fetal toxicity at doses equivalent to or exceeding maximum human doses, including cleft palate and growth retardation 2
- However, these animal findings have not translated to human risk in observational studies 3, 6
- The FDA label states fluticasone "should be used during pregnancy only if the potential benefit justifies the potential risk," which is standard Category C language 2
Practical Management Algorithm
If patient is already on fluticasone pre-pregnancy with good control:
If initiating therapy during pregnancy:
Avoid:
Breastfeeding Compatibility
Fluticasone is compatible with breastfeeding, as systemic absorption from inhaled or intranasal routes is minimal 1